Friday, 29 March 2024


FDA nod for transient elastography device FibroScan

16 April 2013 | Regulatory | By BioSpectrum Bureau

Echosens gets US FDA nod liver diagnosis device FibroScan

Echosens gets US FDA nod liver diagnosis device FibroScan

Singapore: US FDA has given marketing approval to Paris-based Echosens' non-invasive liver diagnosis device, FibroScan. The device is used worldwide both in research and routine clinical practice.

FibroScan is used in the clinical management of patients with liver disease such as chronic viral hepatitis C and B and fatty liver diseases. Based on a technology called transient elastography, FibroScan assesses liver shear wave speed (expressed in meter per second) and equivalent stiffness (expressed in kilopascal) at 50 Hz in a rapid, simple, non-invasive and totally painless way.

Initially introduced in the European market during 2003, FibroScan pioneered the quantitative elastography medical field. It received market clearances in China (2008), Canada (2009), Brazil (2010), Japan (2011) and is currently available in 70 countries.

Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account